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Abstract
Background: Chronic fatigue syndrome (CFS) is a disease of unknown aetiology. Major CFS symptom relief during cancer
chemotherapy in a patient with synchronous CFS and lymphoma spurred a pilot study of B-lymphocyte depletion using the
anti-CD20 antibody Rituximab, which demonstrated significant clinical response in three CFS patients.
Methods and Findings: In this double-blind, placebo-controlled phase II study (NCT00848692), 30 CFS patients were
randomised to either Rituximab 500 mg/m2 or saline, given twice two weeks apart, with follow-up for 12 months.
Xenotropic murine leukemia virus-related virus (XMRV) was not detected in any of the patients. The responses generally
affected all CFS symptoms. Major or moderate overall response, defined as lasting improvements in self-reported Fatigue
score during follow-up, was seen in 10 out of 15 patients (67%) in the Rituximab group and in two out of 15 patients (13%)
in the Placebo group (p = 0.003). Mean response duration within the follow-up period for the 10 responders to Rituximab
was 25 weeks (range 8–44). Four Rituximab patients had clinical response durations past the study period. General linear
models for repeated measures of Fatigue scores during follow-up showed a significant interaction between time and
intervention group (p = 0.018 for self-reported, and p= 0.024 for physician-assessed), with differences between the
Rituximab and Placebo groups between 6–10 months after intervention. The primary end-point, defined as effect on self-
reported Fatigue score 3 months after intervention, was negative. There were no serious adverse events. Two patients in the
Rituximab group with pre-existing psoriasis experienced moderate psoriasis worsening.
Conclusion: The delayed responses starting from 2–7 months after Rituximab treatment, in spite of rapid B-cell depletion,
suggests that CFS is an autoimmune disease and may be consistent with the gradual elimination of autoantibodies
preceding clinical responses. The present findings will impact future research efforts in CFS.
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Introduction
Chronic fatigue syndrome (CFS)/Myalgic encephalomyelitis
(ME) is an illness of unknown aetiology. CFS is characterized by
unexplained severe fatigue, excessive post-exercise exhaustion and
malaise, sleep disturbances, cognitive impairment, sensory hyper-
sensitivity, muscle and joint pain, headache, bowel symptoms, flu-
like episodes and severe impairment of daily functioning. CFS is a
major public health problem, with extensive family and public
costs for medication, nursing and disability [1,2]. The prevalence
estimates vary up to 1%, but is probably 0.1–0.2% of the
population using strict diagnostic criteria [3]. There is at present
no established interventional drug treatment for CFS. However,
infections frequently precede the outbreak of symptoms and
studies point at the immune system being chronically activated [1].
The present line of investigation was initiated after we observed
a patient with CFS who experienced unexpected and marked
recovery of CFS symptoms lasting for five months during and after
cytotoxic chemotherapy for Hodgkin’s disease. We recently
published the first pilot case series describing clinical activity from
B-lymphocyte depletion using the anti-CD20 monoclonal anti-
body Rituximab in three CFS patients [4]. These observations
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suggest that B-cells play a significant role in the ongoing clinical
features of CFS, and provide clues to possible aetiological
mechanisms. To pursue these clues, we performed a randomised,
double-blind and placebo-controlled phase II study using
Rituximab or saline, in 30 CFS patients.
Materials and Methods
Ethics
The study, including amendment, was approved by the
Regional Ethical Committee in Norway, no 200800657-9/
MRO/400, and by the National Medicines Agency. All patients
gave written consent to participate in the study.
Study design, pre-treatment evaluation, and
randomisation
This study (KTS-1-2008, EudraCT no. 2007-007973-22, Clin-
icalTrials.gov NCT00848692) was a single centre, randomised,
double-blind, and placebo-controlled phase II trial comprising 30
patients with chronic fatigue syndrome (CFS). The protocol for
this trial and supporting CONSORT checklist are available as
supporting information (Protocol S1 and Checklist S1). The main
aim was to evaluate the use of B-cell depletion with the anti-CD20
monoclonal antibody Rituximab for CFS symptom relief, during
12 months follow-up. The inclusion criteria were: a diagnosis of
CFS by a neurologist, according to the Fukuda 1994 criteria [5],
age 18–65 years, and written informed consent. Exclusion criteria
were: fatigue not fulfilling CFS criteria, previous malignant disease
(except basal cell carcinoma and cervical dysplasia), previous long-
term immunosuppressive treatment, previous Rituximab treat-
ment, endogenous depression, lack of ability to adhere to protocol,
or evidence of on-going infection.
The primary end-point was effect on CFS symptoms (self-
reported and physician-assessed) three months after intervention.
The secondary endpoints were effects on CFS symptoms (self-
reported and physician-assessed) at 2, 4, 6, 8, 10 and 12 months
after intervention, and assessment of toxicity during 12 months
follow-up. Overall clinical response was also recorded. In
November 2008, an amendment was submitted to the Regional
Ethical Committee (approved January 2009), with addition to the
initial protocol of secondary endpoints at 8 and 10 months after
inclusion. This amendment was based on observation of patient 3
in our pilot case series, who had a major clinical response
occurring late after Rituximab intervention [4]. The sample size
was estimated based on the initial case series [4], showing response
in three out of three consecutive patients, presuming an overall
response rate (ORR) of at least 60%, and one or two responders
among 15 placebo patients.
Most of the participants were recruited from patients referred to
Department of Neurology, Haukeland University Hospital, which
is a tertiary referral centre. After examining the patient hospital
files from approximately 60 patients, 36 patients who after a
telephone interview still seemed to fulfil the inclusion criteria were
invited to a new thorough assessment at the Department of
Oncology, Haukeland University Hospital (ØF and OM). Six out
of these 36 patients chose not to participate (Figure 1).
The pre-treatment evaluation included standard laboratory tests
(haematological, liver function, renal function), HCG to exclude
pregnancy in fertile women, endocrine assessment (thyroid,
adrenal, prolactin), serology for virus (EBV, CMV, HSV, VZV,
Enterovirus, Parvovirus B19, adenovirus), immunophenotyping of
peripheral blood lymphocyte subsets, common autoantibodies,
serum immunoglobulins (IgG, IgM, IgA) with IgG subclasses.
MRI of the brain had been performed in all patients. Further
diagnostic tests were performed if the pre-treatment evaluation
including a thorough clinical examination revealed any relevant
abnormality that could explain the severe fatigue experienced by
the patients.
The 30 patients were randomly allocated to either treatment
with Rituximab or placebo using saline. The randomisation was
performed prior to study start by the Pharmacy at Haukeland
University Hospital, using a simple (unrestricted) method without
blocking. The inclusion period was from June 2008 until June
2009, and the follow-up lasted until June 2010.
According to protocol, four months after the last patient entered
the study (end of October, 2009), the patient files and code for
intervention, Rituximab versus placebo, were inspected by one of
the authors (OD, who did not have patient contact). Based upon
his assessment, a decision was made to prolong the blinding until
the last included patient had finished eight months follow-up (end
of February 2010), at which time 19 patients had finished 10
months follow-up, and 13 patients had finished the complete 12
months observation period. The patients were blinded for group
allocation until the end of follow-up (at least 12 months, up to 20
months).
Treatment schedule, symptom registration, and follow-
up
The patients were in-hospital at the Department of Oncology
for one night when given the intervention. The infusion bags had
double plastic covers to avoid content identification by nurse or
patient. Rituximab 500 mg/m2 (maximum 1000 mg), diluted in
saline to a concentration of 2 mg/ml, or an equal volume of saline,
were given twice two weeks apart, with nurse surveillance and
according to local guidelines used for treating B-cell lymphomas.
No additional Rituximab infusions, or other intervention, were
given during follow-up. All patients were given oral cetirizine
10 mg, paracetamol 1 g, and dexamethasone 8 mg prior to
infusion.
CFS symptom scoring
Before intervention, the patients assessed their CFS disease
status the last three months and recorded their symptoms
according to a visual analogue scale (1–10, 1: no symptom, 10:
very severe symptom) (Figure S1). During follow-up, the patients
recorded overall change in each symptom the preceding two
weeks, as compared to baseline (Figure S2). The visual analogue
scale (0–6) for the follow-up scheme was: 0: Major worsening; 1:
Moderate worsening; 2: Slight worsening; 3: No change; 4: Slight
improvement; 5: Moderate improvement; 6: Major improvement,
similar to a Clinical Global Impression Scale used previously in
CFS [6]. The patients were assessed at the outpatient clinic pre-
treatment, and at 2, 3, 4, 6, 8, 10, and 12 months follow-up. A
separate scheme for physician-assessed symptom change was used,
with the same scale (0–6) and recorded at all visits (Figure S3). Pre-
treatment, and once every month until 10 months follow-up, the
patients recorded the SF-36 short form scheme (Norwegian
translation), which is a general health-related quality of life
questionnaire also assessing eight subdimensions, such as e.g.
physical function, bodily pain, social function and mental health.
Before treatment, and at 4 months follow-up, the patients were in
addition assessed by a neurologist. Patients still in clinical response
were followed also after the study period of 12 months.
Response definitions and statistical analyses
From the self-reported symptoms recorded every second week
(Figure S2, scale 0–6), a Fatigue score was calculated as the mean of
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the four symptoms: Fatigue, Post-exertional exhaustion, Need for
rest, Daily functioning. The Pain score was calculated as the mean
of the two pain symptoms assessed to be characteristic for the
patient (if pre-treatment level $5, among Muscle pain, Joint pain,
Headache, Cutaneous pain). The Cognitive score was the mean of the
three symptoms: Concentration ability, Memory disturbance,
Mental tiredness. The ‘‘Other symptoms score’’ was derived from
the mean of the two symptoms assessed as characteristic for the
patient’s CFS disease, among those with the highest self-reported
pre-treatment level. Also, the patient’s self-reported overall
interpretation of their CFS disease was recorded (‘‘CFS overall
score’’). The Fatigue score, Pain score, Cognitive score, ‘‘CFS overall score’’,
and ‘‘Other symptoms score’’, were plotted every second week, for
each patient in separate diagrams.
The main response was defined from the Fatigue score. A major
response was defined as a Fatigue score $4.5 for at least six
consecutive weeks, also demanding recordings of some fatigue
symptoms as major improvement (value 6) during the response
period. A moderate response was recorded as Fatigue score $4.5 for
at least six consecutive weeks, but without recordings of fatigue
symptoms as major improvement during the response period. The
ORR included both major and moderate responses. The Chi-
square test of proportions was used to compare the ORR between
the Rituximab and Placebo groups. Improvements in Fatigue score
with duration less than six weeks were not recorded as significant
responses, neither were major improvements in Cognitive, Pain or
‘‘Other symptoms’’ score unless followed by a significant improvement
in Fatigue score.
The self-reported Fatigue scores with means for each time interval
during follow-up (i.e. 16–24 weeks), and physician-assessed Fatigue
scores, were plotted. The differences in distribution of Fatigue scores
for the consecutive time intervals during follow-up, between the
Rituximab and Placebo groups, were compared using General
Linear Model (GLM) for repeated measures. Separate analyses for
Figure 1. Study flow-diagram. Approximately 60 patients with CFS diagnosed by a neurologist were identified from the hospital files and
contacted by telephone for an interview, and 36 of these were invited for a further thorough assessment. During 12 months follow-up, one out of 15
patients in the placebo group was excluded from further analysis after 28 weeks due to pregnancy, and one after 42 weeks due to study withdrawal
and patient’s decision to start alternative therapy.
doi:10.1371/journal.pone.0026358.g001
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self-reported and physician-assessed Fatigue scores were made. Five
time intervals (with mean Fatigue scores in each) were included in the
analyses, and Greenhouse-Geisser adjustments were made due to
significant Mauchly’s tests for sphericity. Main effects for time, for
the interaction between time and intervention group, and for the
overall difference between groups (Rituximab versus Placebo) were
assessed. In addition, the estimates for differences in Fatigue score
between groups at the five time intervals during follow-up, each
level compared to baseline, were generated from the GLM
analyses for the interaction time by intervention group (as tests of
within-subjects contrasts).
The response durations were defined as the time interval, during
12 months follow-up, with continuous Fatigue score $4.0 and
including the periods of major or moderate responses. The analyses
of SF-36 short forms, with physical health summary score, mental
health summary score, and scores for the eight SF-36 subdimen-
sions, were generated from a standardised syntax file for each
patient before treatment and monthly until 10 months follow-up.
The changes in SF-36 scores, compared to baseline, were calculated
for each patient during follow-up. For the Rituximab and Placebo
groups, the mean baseline SF-36 scores, and the mean values for
maximum changes in SF-36 scores during follow-up, were
compared using t-tests for independent samples. The statistical
analyses were performed using SPSS for Macintosh, version 19.
Patient characteristics
Between June 2008 and June 2009, 30 patients were randomised.
The demographic data and CFS disease characteristics are shown in
Table 1. The mean age was 37.3 years (80% female) in the
Rituximab group, and 31.5 years (60% female) in the Placebo
group. The mean CFS disease duration was 5.1 years in the
Rituximab group and 8.1 years in the Placebo group, with
maximum disease durations of 13 and 18 years, respectively. A
clear or possible clinical infection preceding CFS onset could be
identified in 73% and 67% of the patients in the Rituximab and
Placebo groups, respectively (Table 1). The frequencies of previous
autoimmune diseases for patients and first-degree relatives are also
shown (Table 1). The baseline symptom scores were derived from
the baseline scheme (Figure S1, scale 1–10) as explained, and are
shown in Table 2. The levels of baseline self-reported Fatigue score,
Cognitive score, Pain score, ‘‘Other symptoms’’ score, and ‘‘CFS overall’’ score,
were similar in the Rituximab and Placebo groups. Generally, the
patients reported a relatively high level of distress for the different
symptom scores, while one patient in the Placebo group reported
almost no pain (score 1.3), and one patient in the Placebo group
reported only mild cognitive symptoms (score 4.0) (Table 2).
B-lymphocytes
Lymphocyte subpopulations, including CD19 positive B cells,
were determined in EDTA anticoagulated blood samples before
treatment, and during all follow-up visits (2, 3, 4, 6, 8, 10 and 12
months). Immunophenotyping of lymphocyte subpopulations was
performed using the BD Multitest 6-color TBNK kit with BD
Trucount Tubes for relative and absolute concentration determina-
tion (BD Biosciences). The samples were prepared according to the
manufacturers instructions and immediately analysed on a BD
Canto II flowcytometer (BD Biosciences). These data were not made
available to the clinical researchers before the end of the study.
Quantitative PCR and PCR for XMRV and MLV, RNase L
genotyping
For details of DNA and RNA purification, cDNA synthesis,
Quantitative PCR for XMRV detection, XMRV and MLV PCR,
Viral amplification, and RNase L genotyping, see Text S1 and
Table S1.
Results
Clinical responses
Overall response was recorded from the self-reported Fatigue
scores, defined as lasting improvements for at least six consecutive
weeks, independent on when the responses occurred during
follow-up. A major response was detected in nine patients in the
Rituximab group, and in one patient in the Placebo group
(p = 0.002). One patient in the each group achieved a moderate
response, giving an total ORR of 10 patients in the Rituximab
group (67%, 95%CI 41%–85%) and two patients in the Placebo
group (13%, 95%CI 4%–38%), p = 0.003 (Table 3).
The effect of intervention was assessed by studying the
interaction effect between time and intervention group, from
GLM for repeated measures of self-reported Fatigue score. There
was a significant interaction time by intervention group in favour
of the Rituximab group (p= 0.018), and an overall difference
between groups (p = 0.045) (Figure 2, panels A and B, Table S2).
Similarly, in GLM for repeated measures of physician-assessed
Fatigue score, the interaction time by intervention group (p= 0.024)
and the overall difference between groups (p = 0.021) were both
significant in favour of the Rituximab group (Figure 2, panels C
and D, Table S2).
From the GLM tests of within-subjects contrasts for the
interaction time by intervention group, with estimates for
differences in Fatigue score between groups at the specific time
intervals, there was no difference in self-reported Fatigue scores
between the Rituximab and Placebo groups at the predetermined
primary endpoint three months after intervention neither from
self-reported nor from physician-assessed symptom scores
(Figure 2, panels A–D). The differences in Fatigue scores between
intervention groups were most evident between 6–10 months after
intervention (Figure 2, panels A–D), i.e. corresponding to
secondary endpoints of the study.
The response durations within 12 months follow-up are shown
in Table 3, with mean duration 25 weeks (range 8–44) for the 10
responders in the Rituximab group. Interestingly, four patients in
the Rituximab group, and one patient in the Placebo group, had
response durations beyond the study period of 12 months, i.e. still
Fatigue score $4 at 12 months. At the time of submission of this
manuscript, two patients in the Rituximab group, and one patient
in the Placebo group, have lasting major responses for all CFS-
related symptoms without signs of relapse, 32, 30, and 23 months
after intervention, respectively.
The self-reported symptoms scores were plotted every second
week for each patient. These data are shown for the 10 responders
in the Rituximab group (Figure 3, panels A–J), and for the two
patients with significant improvement in the Placebo group (Figure
S4, panels A–B). These charts show that symptoms in all the four
main categories tend to follow each other in time. Also included in
these plots are the B-cell numbers during follow-up.
The SF-36 short form, registering health related quality of life,
was filled-in by the patients at baseline and every four weeks during
follow-up. Two patients in the Rituximab group did not fill in
baseline SF-36 form and were excluded from these analyses, one
with a major response and one with no response during follow-up.
The patients reported a low baseline ‘‘physical health summary
score’’, with a mean value of 24 in the Rituximab and 26 in the
Placebo group (scale 0–100, lower value denotes worse symptoms),
while the baseline ‘‘mental health summary score’’ was higher with
a mean value of 46 in both groups (Table 4). There were no
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differences in baseline levels for the different SF-36 subdimensions,
except for ‘‘general health’’, which was lower in the Rituximab
group than in the Placebo group (Table 4). During follow-up, the
maximum changes in SF-36 scores (as compared to the baseline
level) were significantly different in favour of the Rituximab group,
for ‘‘physical health summary score’’ (p= 0.039), and the sub-
dimensions ‘‘physical function’’ (p= 0.014) and ‘‘bodily pain’’
(p= 0.005), while there were trends for difference for ‘‘general
health’’ (p= 0.081) and ‘‘social function’’ (p= 0.081). There were no
differences in maximum changes (compared to baseline) during
follow-up between the Rituximab and Placebo groups, for instance
for the subdimensions ‘‘role emotional’’ (p= 0.44) or ‘‘mental
health’’ (p= 0.81) (Table 4).
In spite of written and verbal information to avoid pregnancy, one
patient was pregnant after 28 weeks follow-up. The randomisation
code for this patient was then revealed. She was allocated to the
placebo group and was withdrawn from further follow-up
registration after 28 weeks. One patient decided to withdraw from
the study after 42 weeks follow-up to start alternative therapy. This
patient proved also to be allocated to the placebo group.
Table 1. Demographic and CFS disease characteristics for patients in the Rituximab and Placebo groups.
Rituximab group Placebo group p-valuea
n=15 n=15
Age, mean (SD) 37.3 years (11.5) 31.5 years (11.6) 0.18
Women, number (%) 12 (80%) 9 (60%) 0.43
CFS disease duration, mean (range) 5.1 years (1.0–13.0) 8.1 years (0.7–18.0) 0.09
Infection before CFS onset Definedb 8 8 0.86
Possible 3 2
No infection 4 5
Clinical course prior studyc Stable 9 12 0.42
Improvement 1 1
Worsening 5 2
Previous autoimmune disease In patientd 3 (20%) 4 (27%) 1.00
In first degree relativee 5 (33%) 7 (47%) 0.46
a: p-values from student’s t-test for continuous data, and from Chi-square tests (or Fisher’s exact test) for categorical characteristics.
b: infectious mononucleosis or unspecific viral infection (6), gastroenteritis (4), respiratory infection (5), urinary infection (1).
c: patient’s assessment of CFS clinical course the last year before inclusion.
d: thyroiditis (2), psoriasis (2), carpal tunnel syndrome (1), diabetes mellitus type I (1), celiac disease (1), juvenile arthritis (1).
e: Bechterew’s disease, rheumatoid arthritis, psoriasis, Cushing’s disease, diabetes mellitus type I, systemic lupus erythematosus, thyroiditis, celiac disease, ulcerative
colitis, Sjogren’s disease, glomerulonephritis.
doi:10.1371/journal.pone.0026358.t001
Table 2. Baseline self-reported symptom scores, RNase L genotype, and XMRV status, for patients in the Rituximab and Placebo
groups.
Rituximab group Placebo group P-valuea
n=15 n=15
Fatigue scoreb, mean (range) 8,1 (7,3–9,8) 7,9 (6,0–9,3) 0.51
Cognitive score 7,7 (5,0–9,7) 7,2 (4,0–9,3) 0.31
Pain score 6,5 (4,0–9,3) 6,2 (1,3–9,0) 0.62
‘‘Other symptoms’’ score 7,8 (5,5–10,0) 7,9 (5,0–10,0) 0.62
‘‘CFS overall’’ score 8,3 (7,0–10,0) 7,9 (6,0–10,0) 0.29
Rnase L genotypec 462 Q/Q 5 6
462 Q/R 10 7
462 R/R 0 2
XMRV status PCRd 0/15 0/15
Coculturee 0/4 0/5
a: p-values from Student’s t-test.
b: baseline self-reported symptom scores, generated as the mean (range) of relevant symptoms, as explained in Materials and Methods (scale 1–10; 1: no symptom, 5:
moderate symptom, 10: very severe symptom, see Figure S1).
c: using Taqman SNP Genotyping (Applied Biosystems, assay c_935391_1).
d: including four Taqman qPCR and four nested PCR setups (see Table S1).
e: performed for nine patients using freshly drawn blood samples. Coculture of patient PBMNC with LNCap prostate cancer cells, and subsequent PCR, as described in
Text S1.
doi:10.1371/journal.pone.0026358.t002
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Adverse effects
Infusion-related complaints and side-effects during 12 months
follow-up are listed in Table 5. There were no serious adverse
events or major toxicity. The complaints during infusion or the
following day were mild and also reported by the placebo patients
(five in the Rituximab group and four in the Placebo group). Two
patients in each group reported slight worsening of CFS the first
two months after intervention (Table 5). Two patients in the
Rituximab group reported feeling uneasy and sleepless from 2–7
and 6–8 months, respectively, synchronous with a clear clinical
response. Two patients in the Rituximab group with pre-existing
psoriasis experienced moderate psoriasis worsening from two
months after intervention, in both preceding a clinical response of
CFS. One patient in the Rituximab group had a five years history
of major CFS symptoms, and reported some lower back pain and
episodes of balanitis from 5–7 months, synchronous with
improvement of his CFS-related muscle pain and headache and
with improving fatigue and cognitive function. His low back pain
disappeared, and after the 12 month study period his CFS
symptoms have resolved further and he is at present back in full-
time work 30 months after intervention.
There were some uncomplicated upper airways infections and
lower urinary tract infections during follow-up, evenly distributed
between the two groups. There were two hospitalisations during
the study period within 12 months follow-up, one in the
Rituximab group due to abdominal pain where a laparoscopy
showed a corpus luteum cyst interpreted as a normal finding, and
one in the Placebo group due to a myocardial infarction.
XMRV
In this study, XMRV could not be detected in any of the 30
patients, using four Taqman quantitative PCR setups, and four
nested PCR approaches (Text S1 and Table S1), and using both
genomic DNA and cDNA from baseline blood samples as
templates. When performing coculture of patient lymphocytes
with LNCaP prostate cancer cells for biological amplification prior
to PCR, XMRV was not detected in any sample. The positive
control was readily amplified in all setups, and both sensitivity and
specificity of the Taqman assays proved to be high, detecting 5–15
viral copies per vial with dilution series of the plasmid spiked in
normal genomic DNA background (data not shown). For details
on analyses, see Supporting information.
RNase L
Results from genotyping of the RNase L Q462R variant are
shown in Table 2. Two patients in the Placebo group had the 462
R/R genotype. The distribution of the Q/Q, Q/R, and R/R
alleles was close to that expected in the general population.
B-lymphocytes
Results from immunophenotyping with B-cell counts, for
patients in the Rituximab group (responders and non-responders)
and the Placebo group, from baseline and at all visits at 1, 2, 3, 4,
6, 8, 10, and 12 months, are shown in Figure 4. At baseline, three
out of 30 patients had a B-cell count below the normal range (110–
4496106/L). All patients in the Rituximab group were B-cell
depleted at one month after the intervention, except for one
patient in which B-cells were not adequately depleted until four
months after intervention (Figure 4). During follow-up, there were
no differences in B-cell levels between patients in the Rituximab
group achieving a response (n = 10), and those with no significant
response (n = 5) (Figure 4). Many patients treated with Rituximab
were not completely B-cell depleted, with values in the range 0–4
(6106/L) (Figure 4). After two infusions of Rituximab two weeks
apart, the B-cell levels started to increase from 4–8 months after
intervention, and four out of 15 patients had regained B-cell
counts in the normal range at the end of follow-up at 12 months.
We also performed Taqman qPCR for the B-cell specific CD19
molecule, normalised according to b-actin mRNA, at baseline and
during follow-up at 4, 6 and 8 months. These data confirmed the
B-cell depletion in Rituximab-treated patients but could not
separate the Rituximab responders and non-responders (data not
shown).
Discussion
In this double-blind and placebo-controlled study, treatment
with Rituximab (two infusions two weeks apart) was associated
with a significant overall clinical response during 12 months
follow-up, as compared to placebo using saline. The ORRs were
67% in the Rituximab group and 13% in the Placebo group.
From GLM for repeated measures, there were significant
interactions between time and intervention group in favour of the
Rituximab group both for self-reported and physician-assessed
Fatigue scores. The differences were most evident corresponding to
secondary endpoints between 6 and 10 months after intervention.
Table 3. Clinical responses in the Rituximab and Placebo groups, and response durations for patients with significant responses,
derived from self-reported Fatigue scores during 12 months follow-up.
Rituximab group Placebo group p-valuea
n=15 n=15
Clinical responsesb Major 9 (60%) 1 (7%) 0.002
Moderate 1 (7%) 1 (7%)
Overall 95% CI 10 (67%) (41%–85%) 2 (13%) (4%–38%) 0.003
Response durationc weeks, mean
(range)
25 (8–.44) n = 10 41 (34–.48) n = 2
a: p-values from Chi-square statistics.
b: One patient was withdrawn from further follow-up registration 28 weeks after inclusion, due to pregnancy. One patient decided to withdraw from the study 42 weeks
after inclusion, due to start of alternative therapy. Both patients were allocated to the placebo group and both reported no significant improvement during follow-up.
These two were included in the analysis for overall response. Overall response including major and moderate responses, number of patients and proportion (%) with
95% confidence intervals.
c: response duration within the 12 months study period, for those achieving a significant response (10 patients in the Rituximab group, and two patients in the Placebo
group). In addition, four out of the 10 Rituximab responders had response durations past the formal study period.
doi:10.1371/journal.pone.0026358.t003
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Figure 2. Fatigue scores in Rituximab and Placebo groups, self-reported and physician-assessed. In panel A, the self-reported Fatigue
scores were calculated for each patient every second week, from the mean of the four symptoms: Fatigue, Post-exertional exhaustion, Need for rest,
Daily functioning. Then the mean values in Fatigue scores for the time intervals during follow-up were plotted. In panel C, the physician-assessed
Fatigue scores were calculated from the mean of the same four symptoms, registered by the physician at the visits in the outpatient clinic. In panel B
and D, estimated marginal means for self-reported and physician-assessed Fatigue scores during follow-up are shown. The scales on Y-axes were 0–6
(0: Major worsening; 1: Moderate worsening; 2: Slight worsening; 3: No change; 4: Slight improvement; 5: Moderate improvement; 6: Major
improvement). The differences in distribution of Fatigue scores during follow-up, between the Rituximab and Placebo groups, were assessed by
General Linear Model (GLM) for repeated measures, analysing the effects of time, the interaction time by intervention group, and the overall
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However, at the predetermined primary endpoint, defined as
effect on CFS symptoms (Fatigue score) at three months after
intervention, there was no difference between the groups.
The change in Fatigue scores was chosen as the main criterion for
clinical response because this is a key symptom defining the CFS
disease. However, with few exceptions, the different symptoms
scores (Fatigue, Cognitive, Pain, ‘‘Other symptoms’’, ‘‘CFS overall’’)
followed each other during responses and relapses, indicating that
a central mechanism for the symptom maintenance is influenced
by the B-cell depletion treatment.
For the 10 Rituximab responders, the response durations varied
from 8–44 weeks (within the 12 month study period). These
responses were considered to have a significant impact on
symptom improvement and quality of life by the patients, by
their families, and by the treating physicians. Importantly, four
patients in the Rituximab group and one in the Placebo group had
response durations beyond 12 months. When submitting this
manuscript, two patients in the Rituximab group and one in the
Placebo group have lasting major responses with no signs of
relapse and are back in full-time work. Two of these patients (one
in each group) had the shortest disease durations, 1.0 and 0.7
years, respectively, and in both CFS was preceded by Epstein-Barr
infection. These two lasting responses may be examples of
spontaneous recovery [7]. The third ‘‘long-time responder’’ with
no later relapse had a 5-year history with major CFS symptoms
before entering the study.
This study with the primary endpoint at three months after
intervention was designed when we had very limited experience
with B-cell depletion in CFS, having observed only two pilot
patients, both with an early response pattern. In the pilot case
series [4] the third patient had major response occurring from 5K
until 9 months after intervention, and with an almost identical
response and relapse pattern after her second Rituximab
treatment. In the present study, only one out of 10 responders
in the Rituximab group had an ‘‘early’’ response pattern with the
major response starting from 2 months, while the remaining nine
responded later, starting to improve from between 3–7 months
after treatment.
The SF-36 short form analyses before intervention confirmed a
low quality of life particularly for the dimensions related to
physical health, while the subdimensions ‘‘mental health’’ and
‘‘role emotional’’ showed higher baseline values. In support for the
overall clinical response data, SF-36 analyses during follow-up
demonstrated significant differences in favour of the Rituximab
group in maximum changes compared to baseline level, for several
subdimensions related to physical health, such as ‘‘physical health
summary score’’, ‘‘physical function’’ and ‘‘bodily pain’’. There
were no significant differences between the groups in maximum
changes for in the subdimensions ‘‘mental health’’ or ‘‘role
emotional’’. These results support the assumption that CFS is not
primarily a mental health disease.
The lack of specific markers of disease and the fact that the CFS
diagnosis is controversial imply that the level of diagnostic
accuracy and adherence to international criteria are likely to be
variable. In this study, patients have been recruited from a tertiary
referral centre and were re-evaluated by the researchers, using the
Fukuda criteria for inclusion. Retrospectively, we checked the 30
patients according to the Clinical Working Case Definition
(‘‘Canadian criteria’’) [8]. Two patients in the placebo group did
not fulfil these criteria, and it could therefore be argued that they
might not have CFS. One of these had almost no pain, and one
had only slight cognitive symptoms and also reported marked
mood disturbances. The latter patient reported major improve-
ment after intervention with saline and was recorded as one of the
two responders in the Placebo group. Generally, the patients
reported a high level of disease-related symptoms prior to entering
the study, with major impact on daily life and ability to participate
in family and social activities. Most of the patients had a long CFS
disease duration, also with a stable or worsening clinical course the
last year before study entry.
A limitation of this study is the lack of predetermined exact
definitions of clinical response with respect to duration and extent
of improvement. Limited experience with the clinical course of
CFS after B-cell depletion when designing the protocol, with
erroneous estimation of time frame for the clinical responses, is a
main reason why the primary end-point is negative. Therefore,
even though this is a randomised, double-blind and placebo-
controlled study, there are also exploratory elements with respect
to response characterization.
Even when interpreting the results with caution, there are
obvious differences between the two groups in favour of the
Rituximab group, from the significant interactions time by
intervention group and also from difference in ORR. Thus, we
have shown that in a subset of CFS patients, Rituximab treatment
with subsequent B-cell depletion results in major responses of CFS
related symptoms, with responses starting to occur between 2 and
7 months after intervention, and with response durations of 2–15
months and in addition two patients with no relapse. Five patients
in the Rituximab group did not achieve a significant response
during follow-up. Whether their CFS pathogeneses are unrelated
to B-lymphocytes, or whether they could achieve a clinical
response through prolonged B-cell depletion with Rituximab
maintenance therapy is at present unknown.
The associations between B-cell depletion and clinical respons-
es, and the time frames for clinical responses delayed 2–7 months
after the initial and rapid B-cell depletion, indicate that CFS may
be an autoimmune disease, often preceded by an infection, and
targeting specific parts of the nervous system. We speculate that
the responses occurring late after intervention could be explained
by the elimination of disease-associated autoantibodies, while the
early response pattern could be related to interaction of B-cells
with T-cells in antigen presentation, as suggested in systemic lupus
erythematosus [9]. Work is in progress in our laboratory to
elucidate the localization and nature of a putative target for an
autoimmune process.
The high rate of CFS in women compared to men is a
suggestion of an underlying autoimmune process. On-going
autoimmune phenomena in CFS have been discussed [10]
perhaps triggered by infections through molecular mimicry,
through structural similarity between a pathogen component
and self-structures [11]. Several autoantibodies have been reported
in CFS, but their pathogenic roles have not been established, for a
review see [10]. In the present study, 23% of the patients had a
previous known autoimmune disease, and 40% had first-degree
relatives with an autoimmune disease. However, there were low
frequencies of positive known common autoantibodies, none had
elevated anti-nuclear antibodies, and two had elevated anti-
thyroid peroxidase antibodies (data not shown). A possible or
difference between intervention groups. Below panels C and D, the estimates for differences in mean Fatigue scores between the Rituximab and
Placebo groups at the specific time intervals during follow-up, with 95% CI and p-values from the GLM (tests of within-subjects contrasts) are
presented. In addition, Holm-Bonferroni step-down adjusted p-values for these time intervals are shown (five comparisons).
doi:10.1371/journal.pone.0026358.g002
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established clinical infection before CFS onset was identified in 21
out of 30 patients included (70%).
A recent study of cytokine patterns in CFS showed attenuated
Th1 and Th17 immune responses, while there was high Th2
marker expression [12]. A Th2 profile with increase in the
numbers of CD4+ and CD8+ T cells secreting IL-4 following
polyclonal stimulation, including in resting cells, was demonstrated
in CFS patients [13].
There are limited data on the role of B-lymphocytes in CFS. One
study of gene expression in peripheral blood mononuclear cells
indicated that B cells might be altered in CFS [14]. Our pilot case
series [4] suggested that B-cell depletion was associated with clinical
improvement in CFS patients. B-cell targeting therapy has been
increasingly used for diverse autoimmune diseases in later years
[15]. The monoclonal anti-CD20 antibody Rituximab has been the
major B-cell depleting agent so far. The B-cells have multiple
immune functions, the main ones being antibody production,
antigen presentation and regulation of the function and activity of
other immune cells, i.e. T-regulatory cells, NK cells and
macrophages [16]. Thus, the total effects of B-cell depletion on
the immune system are likely to be complex and time-dependent.
In Stiff Person Syndrome, which is a rare autoimmune disease
in the central nervous system with autoantibodies targeting
glutamic acid decarboxylase (GAD65), the humoral autoimmune
response was shown to consist of a Rituximab-sensitive part
rapidly cleared after treatment, and a Rituximab-resistant part
from long-lived and persistent plasma cells acting as a reservoir for
secretion of autoantibodies. This may be one mechanism for lack
of effect from B-cell depletion therapy [17].
An alternative explanation for the observed clinical improve-
ment from B-cell depletion could be elimination or reduction of B-
lymphotrophic viruses such as cytomegalovirus (CMV) or Epstein-
Barr virus (EBV). A recent study [18] showed clinical benefit from
long-term valacyclovir or valgancicliovir treatment in a subset of
CFS patients with evidence of active on-going herpes virus
infections, also shown in a previous small study of 12 patients with
elevated antibodies to EBV or human herpes virus 6 (HHV-6)
[19]. We find the delayed clinical responses after B-cell depletion,
Figure 3. CFS symptom changes during follow-up for patients in the Rituximab group with significant responses. In panels A–J,
changes in Fatigue score (black), Cognitive score (red), Pain score (green), ‘‘Other symptoms’’ score (orange), and ‘‘CFS overall’’ score (blue), during 12
months follow-up are shown for the 10 patients in the Rituximab group with significant improvement. The scales on Y-axes were 0–6 (0: Major
worsening; 1: Moderate worsening; 2: Slight worsening; 3: No change; 4: Slight improvement; 5: Moderate improvement; 6: Major improvement). Also
shown are the B-cell numbers from immunophenotyping of peripheral blood mononuclear cells during follow-up (6106/L).
doi:10.1371/journal.pone.0026358.g003
Table 4. SF-36 scores, baseline levels (0–100) and maximum changes (%) during follow-up, for patients in the Rituximab and
Placebo groups.
Rituximab group Placebo group p-valuea
n=13b n=15
Physical health summary score baselinec, mean (SD) 24 (5) 26 (6) 0.41
max changed, mean (SD) 54% (46) 26% (17) 0.039
Mental health summary score baseline, mean (SD) 46 (11) 46 (8) 0.99
max change, mean (SD) 9% (54) 5% (32) 0.84
Physical function baseline, mean (SD) 34 (6) 35 (7) 0.71
max change, mean (SD) 39% (33) 11% (22) 0.014
Role physical baseline, mean (SD) 28 (8) 28 (2) 0.92
max change, mean (SD) 27% (35) 20% (35) 0.64
Bodily pain baseline, mean (SD) 32 (8) 34 (9) 0.62
max change, mean (SD) 40% (31) 8% (24) 0.005
General health baseline, mean (SD) 27 (5) 33 (6) 0.007
max change, mean (SD) 36% (51) 9% (23) 0.081
Vitality baseline, mean (SD) 35 (8) 31 (5) 0.15
max change, mean (SD) 24% (50) 31% (30) 0.66
Social function baseline, mean (SD) 21 (9) 21 (8) 0.92
max change, mean (SD) 98% (110) 38% (62) 0.081
Role emotional baseline, mean (SD) 50 (12) 51 (11) 0.74
max change, mean (SD) 10% (53) 24% (42) 0.44
Mental health baseline, mean (SD) 49 (9) 50 (7) 0.69
max change, mean (SD) 6% (36) 3% (22) 0.81
a: p-values from Student’s t-test for independent samples.
b: two patients in the Rituximab group did not fill in baseline SF-36 form, one with major response and one non-responder.
c: range for baseline SF-36 scores is 0–100 (lower score denotes increasing symptoms).
d: maximum change (%) in SF-36 scores during follow-up, as compared to baseline. The patients filled in SF-36 forms at baseline and then every month until 10 months
after intervention. Five out of 143 forms were missing (not filled in) in the Rituximab group (excluding the two patients with no baseline scheme), and nine out of 161
forms were missing in the Placebo group (one patient withdrawn after 28 weeks due to pregnancy).
doi:10.1371/journal.pone.0026358.t004
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that we observed in the majority of responders, difficult to explain
from a viral elimination mechanism. In our opinion, this response
pattern is more compatible with the gradual elimination of an
autoantibody, perhaps by preferential elimination of short-lived
pre-plasma cells. Although poorly understood, immune system
alterations seen in stress-related diseases such as post-traumatic
stress disorder could also be relevant for the effects of B-cell
depletion seen in CFS [20].
In this study there were no serious adverse events. Two
hospitalisations (one in each group) during follow-up were not
perceived to be caused by the intervention. There were no serious
infections. Two patients in the Rituximab group (both responders)
had a slight to moderate worsening of pre-existing psoriasis, which
could be a direct side-effect from the intervention. Two patients in
the Rituximab group (also responders) felt uneasy and sleepless
while improving in CFS symptoms. These symptoms are not usual
Table 5. Infusion-related complaints during or the first 24 hours after infusion, and side-effects during 12 months follow-up, in the
Rituximab and Placebo groups.
Rituximab group Placebo group
n=15 n=15
Infusion-related complaints Palpitations 1 (7%) 1 (7%)
Slight itching 2 (13%) 0
Nausea 0 1
Discomfort 2 (13%) 2 (13%)
Slight CFS worsening the first two months 2 (13%) 2 (13%)
Irregular menstrual bleeding the first two months 1 (7%) 0
Feeling uneasy and sleepless 6–8 months 1 (7%) 0
2–7 months 1 (7%) 0
Slight facial acne 1 (7%) 0
Psoriasis worsening 2–12 months 2 (13%) 0
Low back pain and balanitis 5–7 months 1 (7%) 0
doi:10.1371/journal.pone.0026358.t005
Figure 4. B-lymphocytes during follow-up. B-cell numbers from immunophenotyping of peripheral blood during follow-up are shown, for
patients in the Placebo group (black, n = 15), patients in the Rituximab group with significant response (red, n = 10), and patients in the Rituximab
group with no response (blue, n = 5). The B-cell value zero was substituted by 0.1 (to be able to plot on the log scale). B-lymphocyte counts6106/L
(normal range 110–449). The error bars denote mean 6 SEM.
doi:10.1371/journal.pone.0026358.g004
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side effects from treatment of B-cell lymphomas and may be
related to the effects of B-cell depletion on the underlying CFS
disease rather than direct side-effects from Rituximab. The
infusion-related complaints were generally mild and reported
both from the Rituximab and Placebo groups. Interestingly, no
side-effects during follow-up were reported from the five non-
responders in the Rituximab group.
Current use of Rituximab in autoimmune diseases has been
discussed [21], and a recent review on the safety in rheumatoid
arthritis concluded that Rituximab is well tolerated with no
increasing rate of serious infections [22]. Even if serious side-effects
including reactivation of viral infections such as hepatitis B are
very rare, they may appear [23]. A study reviewing progressive
multifocal leukoencephalopathy (PML) cases in patients treated
with Rituximab, from available databases including the Food and
Drug Administration, the manufacturer, physicians, and including
a literature review from 1997–2008, identified 52 patients with
lymphoproliferative disorders and five patients with autoimmune
diseases [24]. All had received either chemotherapy or other
immunosuppressive treatment in addition to Rituximab, and to
our knowledge PML has not been reported in patients receiving
Rituximab monotherapy. The absolute risk of PML is difficult to
estimate, but is very low.
Although B-cell depletion has a major impact on the immune
system, it can be argued that the persistent and often devastating
symptoms of CFS and the very low quality of life in many sufferers
justify the use of Rituximab in carefully evaluated CFS patients.
There has been an intense focus on XMRV as a possible causal
gammaretroviral infection in CFS patients since the first report in
October 2009 [25]. One later study demonstrated presence of
closely related MLV in CFS patients [26]. However, several other
studies have not been able to reproduce these findings and
reported no evidence for XMRV infection in CFS, as examples
[27–30]. We have not been able to demonstrate XMRV or MLV
infection in any of the 30 patients included in this study, despite
multiple different approaches including four different highly
sensitive Taqman qPCR and four nested PCR approaches, and
using both genomic DNA and cDNA as templates. We also
performed coculture of patient peripheral blood mononuclear cells
with LNCaP prostate cancer cells for biological virus amplification
prior to PCR, also with no XMRV positive cases.
In conclusion, we have shown that B-lymphocyte depletion with
the monoclonal anti-CD20 antibody Rituximab, two infusions two
weeks apart, is associated with significant, though generally
transient clinical responses, with CFS symptom improvement in
two thirds of the included patients. No major toxicity was observed
in 12 months follow-up. Even though this study is small, it is a
randomised, double-blind, and placebo-controlled study showing
significant differences in favour of the Rituximab group, and with
general improvement of all CFS symptoms. Thus, we believe that
B-cell depletion targets a central player in the pathogenesis of the
CFS disease, directly or indirectly. Whether this mechanism
applies to specific subsets of CFS patients or the group as a whole
is a subject for further research. While this study can be
interpreted as preliminary, being the first to describe the treatment
principle in CFS except for our pilot case series [4], we believe the
results are best compatible with an autoimmune disease mecha-
nism and that the presented findings may have a major impact on
the direction of biomedical research in CFS. Based on new pilot
patient experiences, we have now started two new open-label
phase-II studies investigating Rituximab treatment with two
infusions two weeks apart (as in the present study) followed by
maintenance Rituximab infusions at 3, 6, 10 and 15 months, to
further explore this treatment principle in CFS (ClinicalTrials.gov,
NCT01156909 and NCT01156922). The present study may be
interpreted as a ‘‘proof of principle’’. The next studies will indicate
to what extent the patients actually over time may recover through
B-cell depletion treatment.
Supporting Information
Text S1 Materials and Methods (DNA and RNA purifi-
cation, and cDNA synthesis. Quantitative PCR for XMRV
detection. XMRV and MLV PCR. Viral amplification. RNase L
Genotyping).
(PDF)
Figure S1 Scheme for patient’s self-reported baseline
CFS symptoms. Before intervention, the patients assessed their
CFS disease and recorded their symptoms the last three months
according to a visual analogue, scale 1–10 (1: no symptom; 5:
moderate symptom; 10: very severe symptom).
(TIF)
Figure S2 Scheme for patient’s self-reported CFS symp-
tom change during follow-up. During 12 months follow-up,
the patients recorded symptom changes the preceding two weeks,
as compared to baseline. The visual analogue scale for the follow-
up scheme was 0–6 (0: Major worsening; 1: Moderate worsening;
2: Slight worsening; 3: No change; 4: Slight improvement; 5:
Moderate improvement; 6: Major improvement).
(TIF)
Figure S3 Scheme for physician-assessed CFS symp-
toms, at baseline and during follow-up. The patients were
assessed at the outpatient clinic before intervention, and at 2, 3, 4,
6, 8, 10, and 12 months follow-up. The physicians assessed the
patients CFS disease and recorded the symptoms according to
visual analogue scales. Before intervention, the scale was 1–10 (1:
no symptom; 5: moderate symptom; 10: very severe symptom).
During 12 months follow-up, the physicians assessed patients
symptom changes as compared to baseline, scale 0–6 (0: Major
worsening; 1: Moderate worsening; 2: Slight worsening; 3: No
change; 4: Slight improvement; 5: Moderate improvement; 6:
Major improvement).
(TIF)
Figure S4 CFS symptom changes during follow-up, for
the two patients in the Placebo group with significant
improvement. In panels A and B, changes in Fatigue score (black),
Cognitive score (red), Pain score (green), ‘‘Other symptoms’’ score (orange),
and ‘‘CFS overall’’ score (blue), during 12 months follow-up are
shown for the two patients in the Placebo group with significant
improvement. The scales on Y-axes were 0–6 (0: Major worsening;
1: Moderate worsening; 2: Slight worsening; 3: No change; 4:
Slight improvement; 5: Moderate improvement; 6: Major
improvement). Also shown are the B-cell numbers from immuno-
phenotyping of peripheral blood mononuclear cells during follow-
up (6106/L).
(TIF)
Table S1 Primers and probes for detection of Xenotro-
pic murine leukemia virus-related virus (XMRV) and
MLV-related virus.
(PDF)
Table S2 Effects of intervention group (Rituximab
versus Placebo) on Fatigue score during 12 months
follow-up, using General Linear Model for repeated
measures, with separate analyses for self-reported and
physician-assessed symptoms.
(DOC)
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